Tomita et al reported the SIL index (stage, interleukin, LDH) for evaluating a patient with diffuse large B-cell lymphoma. This can help to identify a patient who may require more aggressive management. The authors are from Yokohama City University, Kanagawa Cancer Center, Fujisawa City Hospital and Yamato City Hospital in Japan.
Patient selection: diffuse large B-cell lymphoma (DLBCL)
Parameters:
(1) Ann Arbor stage (S)
(2) serum soluble interleukin-2 receptor in U/mL (I)
(3) serum LDH (L) relative to the upper limit of the normal reference range (L)
Parameter
Finding
Points
stage
1 or 2
0
3 or 4
1
soluble interleukin-2 receptor (sIL-2R)
<= 2,500 U/mL
0
> 2,500 U/mL
1
serum LDH
<= ULN
0
> ULN
1
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 3
• A score >= 2 indicates high risk disease (overall 4-year survival 67%).
• A score of 0 or 1 indicates standard risk (overall 4-year survival 91%).
To read more or access our algorithms and calculators, please log in or register.
